Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06843447 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
A Phase 1 study of Ovarian Cancer Recurrent, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 280
- Enrollment target
- 16
- Study locations
NCT06843447 is a Phase 1 study of Ovarian Cancer Recurrent that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 280 participants, above the 67-participant average among 4 other Ovarian Cancer Recurrent trials with a reported enrollment target (318% higher). The trial reports 16 study locations across 10 states.
The verdict
NCT06843447, a Phase 1 study of Ovarian Cancer Recurrent, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 280 participants
- Enrollment target
- 16
- Study locations
Study Summary
Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes. Standard treatment (usual treatment) for people with relapsed high-grade serous ovarian cancer may include: * Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing * Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Rescue Medication
- BIOLOGICAL Raludotatug Deruxtecan
- BIOLOGICAL Bevacizumab
Study Locations (16)
Other
- Rambam Health Care Campus ( Site 0202) - Haifa
- Shaare Zedek Medical Center ( Site 0201) - Jerusalem
- Sheba Medical Center ( Site 0200) - Ramat Gan
- Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300) - Barcelona
- Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303) - Madrid
- Hospital Universitario 12 de Octubre ( Site 0304) - Madrid
England
- Royal Marsden Hospital ( Site 0402) - Fulham
- The Royal Marsden NHS Foundation Trust. ( Site 0403) - Sutton
Kentucky
- The University of Louisville, James Graham Brown Cancer Center ( Site 0009) - Louisville
New York
- Memorial Sloan Kettering Cancer Center ( Site 0003) - New York
Texas
- Houston Methodist Hospital ( Site 0010) - Houston
Utah
- START Mountain Region ( Site 0008) - West Valley City
Virginia
- University of Virginia Health System ( Site 0011) - Charlottesville
Barcelona
- Institut Català d'Oncologia - L'Hospitalet ( Site 0302) - L'Hospitalet de Llobregat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2029-03-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06843447
The ClinicalTrials.gov registry entry for NCT06843447 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 67-participant average among 4 other Ovarian Cancer Recurrent trials with a reported enrollment target (318% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer Recurrent appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT06843447 reports 16 study locations spanning 10 distinct geographic areas - top geographies include Other, England, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06843447 about?
NCT06843447 is a clinical study titled "A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)". Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or ...
What is the current status of trial NCT06843447?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 280 participants. The study started on 2025-04-15. Estimated completion is 2029-03-27.
What conditions does trial NCT06843447 study?
This clinical trial studies the following conditions: Ovarian Cancer Recurrent.
What interventions are being tested in trial NCT06843447?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Rescue Medication (DRUG), Raludotatug Deruxtecan (BIOLOGICAL), Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06843447?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06843447 being conducted?
This trial has 16 study locations across Kentucky, New York, Texas, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer Recurrent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
RECRUITING · Phase 1
-
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.